Carbamoyl phosphate synthetase I deficiency
Carbamoyl Phosphate Synthetase I Deficiency (CPS1 deficiency) is a rare genetic disorder that affects the urea cycle, a series of biochemical processes in the liver responsible for removing ammonia from the blood and converting it into urea, which is then excreted in the urine. CPS1 deficiency is caused by mutations in the CPS1 gene, leading to a deficiency or dysfunction of the enzyme carbamoyl phosphate synthetase I. This enzyme plays a critical role in the first step of the urea cycle, and its deficiency leads to an accumulation of ammonia and other toxic substances in the blood, which can cause serious health problems, including brain damage, coma, and if untreated, death.
Symptoms[edit | edit source]
The symptoms of CPS1 deficiency typically appear in the first few days of life and may include:
- Lethargy
- Poor feeding
- Vomiting
- Seizures
- Hypothermia (abnormally low body temperature)
- Respiratory distress
- Coma
In less severe cases, symptoms may appear later in childhood or adulthood and may be triggered by episodes of high protein intake, illness, or other stressors.
Diagnosis[edit | edit source]
Diagnosis of CPS1 deficiency involves a combination of clinical evaluation, laboratory testing, and genetic testing. Laboratory tests may show elevated levels of ammonia in the blood, while genetic testing can identify mutations in the CPS1 gene.
Treatment[edit | edit source]
Treatment for CPS1 deficiency is aimed at reducing ammonia levels in the blood and may include:
- A low-protein diet to reduce the amount of ammonia produced in the body
- Medications to remove ammonia from the body, such as sodium benzoate or sodium phenylbutyrate
- Liver transplant in severe cases
Prognosis[edit | edit source]
The prognosis for individuals with CPS1 deficiency varies depending on the severity of the condition and the effectiveness of treatment. Early diagnosis and treatment are critical for preventing serious complications.
Epidemiology[edit | edit source]
CPS1 deficiency is a very rare disorder, with an estimated incidence of 1 in 800,000 to 1 in 1,000,000 live births worldwide.
Carbamoyl phosphate synthetase I deficiency Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD